AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Apr 1, 2021
31637_dirs_2021-03-31_e54b3e7d-ebcd-4429-8988-ac234e5bb9be.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-03-29
Reporting Person: Ho Carole (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-29 | Common Stock | S | 2822 | $54.616 | Disposed | 162319 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 25000 | Indirect |
| Common Stock | 82382 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $54.08 to $54.93 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F4: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
F5: Includes 80,906 restricted stock units.